B.Riley FBR Thinks Cumberland Pharmaceuticals Inc.’s Stock is Going to Recover


In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), with a price target of $8.80. The company’s shares closed yesterday at $5.61, close to its 52-week low of $5.51.

According to TipRanks.com, D’silva is a 5-star analyst with an average return of 23.9% and a 53.7% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Oramed Pharmaceuticals, and Sorrento Therapeutics.

Currently, the analyst consensus on Cumberland Pharmaceuticals Inc. is a Moderate Buy with an average price target of $8.80.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.96 and a one-year low of $5.51. Currently, Cumberland Pharmaceuticals Inc. has an average volume of 12.24K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of brands for the hospital acute care, gastroenterology, and oncology. Its product brands include acetadote, caldolor, kristalose, hepatoren, omeclamox, vaprisol, boxaban, vasculan, ethyol, portaban, and totect.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts